Pharmabiotics as an emerging medication for metabolic syndrome and its related diseases

Molecules

Volumn 22, Issue 10, 2017, Pages

  Nguyen, Thi Thanh Binh ^a   Jin, Yan Yan ^a   Chung, Hea Jong ^b   Hong, Seong Tschool ^a  

^a Chonbuk National University   (South Korea)

^b Seonam University   (South Korea)

Author keywords

Cardiovascular diseases; Diabetes; Dyslipidemia; Gut microbiota; Hypertension; Metabolic syndrome; Obesity; Pharmabiotics

Indexed keywords

PROBIOTIC AGENT;

CARDIOVASCULAR DISEASE; COMPLICATION; DIABETES MELLITUS; HUMAN; HYPERTENSION; INTESTINE FLORA; METABOLIC SYNDROME X; OBESITY; RISK FACTOR;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS; GASTROINTESTINAL MICROBIOME; HUMANS; HYPERTENSION; METABOLIC SYNDROME; OBESITY; PROBIOTICS; RISK FACTORS;

EID: 85032617981     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules22101795     Document Type: Review

References (156)

1. Alwan, A. Global Status Report onNoncommunicableDiseases 2010;WorldHealthOrganization: Geneva, Switzerland, 2011.
2. Eckel, R. H.; Alberti, K.; Grundy, S. M.; Zimmet, P. Z. The metabolic syndrome. Lancet 2010, 375, 181-183. [CrossRef]
3. Samson, S. L.; Garber, A. J. Metabolic syndrome. Endocrinol. Metab. Clin. N. Am. 2014, 43, 1-23. [CrossRef] [PubMed]
4. Kaur, J. A comprehensive review on metabolic syndrome. Cardiol. Res. Pract. 2014, 2014, 943162. [CrossRef] [PubMed]
5. Kassi, E.; Pervanidou, P.; Kaltsas, G.; Chrousos, G. Metabolic syndrome: Definitions and controversies. BMC Med. 2011, 9, 48. [CrossRef] [PubMed]
6. Abubakar, I.; Tillmann, T.; Banerjee, A. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: A systematic analysis for the global burden of disease study 2013. Lancet 2015, 385, 117-171.
7. Van Vliet-Ostaptchouk, J. V.; Nuotio, M.-L.; Slagter, S. N.; Doiron, D.; Fischer, K.; Foco, L.; Gaye, A.; Gögele, M.; Heier, M.; Hiekkalinna, T. The prevalence of metabolic syndrome and metabolically healthy obesity in europe: A collaborative analysis of ten large cohort studies. BMC Endocr. Disord. 2014, 14, 9. [CrossRef] [PubMed]
8. Langan, S. M.; Seminara, N. M.; Shin, D. B.; Troxel, A. B.; Kimmel, S. E.; Mehta, N. N.; Margolis, D. J.; Gelfand, J. M. Prevalence of metabolic syndrome in patients with psoriasis: A population-based study in the united kingdom. J. Investig. Dermatol. 2012, 132, 556-562. [CrossRef] [PubMed]
9. Flegal, K. M.; Carroll, M. D.; Ogden, C. L.; Curtin, L. R. Prevalence and trends in obesity among us adults, 1999-2008. JAMA 2010, 303, 235-241. [CrossRef] [PubMed]
10. Afshin, A.; Forouzanfar, M. H.; Reitsma, M. B.; Sur, P.; Estep, K.; Lee, A.; Marczak, L.; Mokdad, A. H.; Moradi-Lakeh, M.; Naghavi, M. Health effects of overweight and obesity in 195 countries over 25 years. N. Engl. J. Med. 2017, 377, 13-27. [PubMed]
11. Menke, A.; Casagrande, S.; Geiss, L.; Cowie, C. C. Prevalence of and trends in diabetes among adults in the united states, 1988-2012. JAMA 2015, 314, 1021-1029. [CrossRef] [PubMed]
12. Guariguata, L.; Whiting, D.; Hambleton, I.; Beagley, J.; Linnenkamp, U.; Shaw, J. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res. Clin. Pract. 2014, 103, 137-149. [CrossRef] [PubMed]
13. World Health Organization. Global Report On Diabetes;World Health Organization: Geneva, Switzerland, 2016.
14. King, H.; Aubert, R. E.; Herman, W. H. Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections. Diabetes Care 1998, 21, 1414-1431. [CrossRef] [PubMed]
15. Feigin, V. L.; Roth, G. A.; Naghavi, M.; Parmar, P.; Krishnamurthi, R.; Chugh, S.; Mensah, G. A.; Norrving, B.; Shiue, I.; Ng, M. Global burden of stroke and risk factors in 188 countries, during 1990-2013: A systematic analysis for the global burden of disease study 2013. Lancet Neurol. 2016, 15, 913-924. [CrossRef]
16. Daviglus, M. L.; Talavera, G. A.; Avilés-Santa, M. L.; Allison, M.; Cai, J.; Criqui, M. H.; Gellman, M.; Giachello, A. L.; Gouskova, N.; Kaplan, R. C. Prevalence of major cardiovascular risk factors and cardiovascular diseases among hispanic/latino individuals of diverse backgrounds in the united states. JAMA 2012, 308, 1775-1784. [CrossRef] [PubMed]
17. Dahlöf, B. Cardiovascular disease risk factors: Epidemiology and risk assessment. Am. J. Cardiol. 2010, 105, 3A-9A. [CrossRef] [PubMed]
18. Towfighi, A.; Saver, J. L. Stroke declines from third to fourth leading cause of death in the united states. Stroke 2011, 42, 2351-2355. [CrossRef] [PubMed]
19. Scholze, J.; Alegria, E.; Ferri, C.; Langham, S.; Stevens, W.; Jeffries, D.; Uhl-Hochgraeber, K. Epidemiological and economic burden of metabolic syndrome and its consequences in patients with hypertension in germany, spain and italy; a prevalence-based model. BMC Public Health 2010, 10, 529. [CrossRef] [PubMed]
20. De Onis, M.; Blössner, M.; Borghi, E. Global prevalence and trends of overweight and obesity among preschool children. Am. J. Clin. Nutr. 2010, 92, 1257-1264. [CrossRef] [PubMed]
21. Friend, A.; Craig, L.; Turner, S. The prevalence of metabolic syndrome in children: A systematic review of the literature. Metab. Syndr. Relat. Disord. 2013, 11, 71-80. [CrossRef] [PubMed]
22. Wang, Y.; Lim, H. The Global Childhood Obesity Epidemic and the Association between Socio-Economic Status and Childhood Obesity; Taylor & Francis: Boca Raton, FL, USA, 2012.
23. Poyrazoglu, S.; Bas, F.; Darendeliler, F. Metabolic syndrome in young people. Curr. Opin. Endocrinol. Diabetes Obes. 2014, 21, 56-63. [CrossRef] [PubMed]
24. Ng, M.; Fleming, T.; Robinson, M.; Thomson, B.; Graetz, N.; Margono, C.; Mullany, E. C.; Biryukov, S.; Abbafati, C.; Abera, S. F. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: A systematic analysis for the global burden of disease study 2013. Lancet 2014, 384, 766-781. [CrossRef]
25. Hills, A. P.; Mokhtar, N.; Brownie, S.; Byrne, N. M. Childhood obesity in Asia: The value of accurate body composition methodology. Asia Pac. J. Clin. Nutr. 2014, 23, 339-343. [PubMed]
26. Mitchell, A. J.; Vancampfort, D.; Sweers, K.; van Winkel, R.; Yu, W.; De Hert, M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders-A systematic review and meta-analysis. Schizophr. Bull. 2011, 39, 306-318. [CrossRef] [PubMed]
27. Vancampfort, D.; Vansteelandt, K.; Correll, C. U.; Mitchell, A. J.; De Herdt, A.; Sienaert, P.; Probst, M.; De Hert, M. Metabolic syndrome and metabolic abnormalities in bipolar disorder: A meta-analysis of prevalence rates and moderators. Am. J. Psychiatry 2013, 170, 265-274. [CrossRef] [PubMed]
28. Grundy, S. M. Drug therapy of the metabolic syndrome: Minimizing the emerging crisis in polypharmacy. Nat. Rev. Drug Discov. 2006, 5, 295-309. [CrossRef] [PubMed]
29. Ioannides-Demos, L. L.; Piccenna, L.; McNeil, J. J. Pharmacotherapies for obesity: Past, current, and future therapies. J. Obes. 2010, 2011, 179674. [CrossRef] [PubMed]
30. Kang, J. G.; Park, C.-Y. Anti-obesity drugs: A review about their effects and safety. Diabetes Metab. J. 2012, 36, 13-25. [CrossRef] [PubMed]
31. Marvasti, T. B.; Adeli, K. Pharmacological management of metabolic syndrome and its lipid complications. DARU J. Pharma. Sci. 2010, 18, 146-154.
32. Beckett, R. D.; Schepers, S. M.; Gordon, S. K. Risk of new-onset diabetes associated with statin use. SAGE Open Med. 2015, 3, 2050312115605518. [CrossRef] [PubMed]
33. Koh, K. K.; Quon, M. J.; Han, S. H.; Lee, Y.; Kim, S. J.; Shin, E. K. Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J. Am. Coll. Cardiol. 2010, 55, 1209-1216. [CrossRef] [PubMed]
34. Ebrahimof, S.; Mirmiran, P. Nutritional approaches for prevantion and treatment of metabolic syndrome in adults. J. Paramed. Sci. 2013, 4. [CrossRef]
35. Durstine, J. L.; Gordon, B.; Wang, Z.; Luo, X. Chronic disease and the link to physical activity. J. Sport Health Sci. 2013, 2, 3-11. [CrossRef]
36. Sommer, F.; Bäckhed, F. The gut microbiota-Masters of host development and physiology. Nat. Rev. Microbiol. 2013, 11, 227-238. [CrossRef] [PubMed]
37. Tremaroli, V.; Bäckhed, F. Functional interactions between the gut microbiota and host metabolism. Nature 2012, 489, 242-249. [CrossRef] [PubMed]
38. Clemente, J. C.; Ursell, L. K.; Parfrey, L. W.; Knight, R. The impact of the gut microbiota on human health: An integrative view. Cell 2012, 148, 1258-1270. [CrossRef] [PubMed]
39. Torgerson, J. S.; Hauptman, J.; Boldrin, M. N.; Sjostrom, L. Xenical in the prevention of diabetes in obese subjects (xendos) study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004, 27, 155-161. [CrossRef] [PubMed]
40. Douglas, I. J.; Langham, J.; Bhaskaran, K.; Brauer, R.; Smeeth, L. Orlistat and the risk of acute liver injury: Self controlled case series study in uk clinical practice research datalink. BMJ (Clin. Res. Ed.) 2013, 346, f1936. [CrossRef] [PubMed]
41. Garcia, S. B.; Barros, L. T.; Turatti, A.; Martinello, F.; Modiano, P.; Ribeiro-Silva, A.; Vespucio, M. V.; Uyemura, S. A. The anti-obesity agent orlistat is associated to increase in colonic preneoplastic markers in rats treated with a chemical carcinogen. Cancer Lett. 2006, 240, 221-224. [CrossRef] [PubMed]
42. Takayama, T.; Katsuki, S.; Takahashi, Y.; Ohi, M.; Nojiri, S.; Sakamaki, S.; Kato, J.; Kogawa, K.; Miyake, H.; Niitsu, Y. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N. Engl. J. Med. 1998, 339, 1277-1284. [CrossRef] [PubMed]
43. Franson, K.; Rossner, S. Fat intake and food choices during weight reduction with diet, behavioural modification and a lipase inhibitor. J. Intern. Med. 2000, 247, 607-614. [CrossRef] [PubMed]
44. Thomsen, W. J.; Grottick, A. J.; Menzaghi, F.; Reyes-Saldana, H.; Espitia, S.; Yuskin, D.; Whelan, K.; Martin, M.; Morgan, M.; Chen, W.; et al. Lorcaserin, a novel selective human 5-hydroxytryptamine2c agonist: In vitro and in vivo pharmacological characterization. J. Pharmacol. Exp. Ther. 2008, 325, 577-587. [CrossRef] [PubMed]
45. Higgins, G. A.; Fletcher, P. J. Therapeutic potential of 5-ht2c receptor agonists for addictive disorders. ACS Chem. Neurosci. 2015, 6, 1071-1088. [CrossRef] [PubMed]
46. Smith, B. M.; Smith, J. M.; Tsai, J. H.; Schultz, J. A.; Gilson, C. A.; Estrada, S. A.; Chen, R. R.; Park, D. M.; Prieto, E. B.; Gallardo, C. S.; et al. Discovery and sar of new benzazepines as potent and selective 5-ht(2c) receptor agonists for the treatment of obesity. Bioorg. Med. Chem. Lett. 2005, 15, 1467-1470. [CrossRef] [PubMed]
47. Millan, M. J. Serotonin 5-ht2c receptors as a target for the treatment of depressive and anxious states: Focus on novel therapeutic strategies. Therapie 2005, 60, 441-460. [CrossRef] [PubMed]
48. Lorcaserin. In obesity: Unacceptable risks. Prescrire Int. 2014, 23, 117-120.
49. Lipska, K. J.; Bailey, C. J.; Inzucchi, S. E. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 2011, 34, 1431-1437. [CrossRef] [PubMed]
50. Klepser, T. B.; Kelly, M. W. Metformin hydrochloride: An antihyperglycemic agent. Am. J. Health Syst. Pharm. 1997, 54, 893-903. [PubMed]
51. Norris, S. L.; Carson, S.; Thakurta, S.; Chan, B. K. S. Drug class reviews. In Drug Class Review: Thiazolidinediones: Final Report Update 1; Oregon Health & Science University Oregon Health & Science University: Portland, OR, USA, 2008.
52. Byrne, C. D.; Wild, S. H. Review: Thiazolidinediones increase risk for heart failure in type 2 diabetes. Evid. Based Med. 2008, 13, 8. [CrossRef] [PubMed]
53. Seino, S. Cell signalling in insulin secretion: The molecular targets of atp, camp and sulfonylurea. Diabetologia 2012, 55, 2096-2108. [CrossRef] [PubMed]
54. Blickle, J. F. Meglitinide analogues: A review of clinical data focused on recent trials. Diabetes Metab. 2006, 32, 113-120. [CrossRef]
55. Singh, S.; Chang, H. Y.; Richards, T. M.; Weiner, J. P.; Clark, J. M.; Segal, J. B. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: A population-based matched case-control study. JAMA Intern. Med. 2013, 173, 534-539.
56. Bunck, M. C.; Diamant, M.; Corner, A.; Eliasson, B.; Malloy, J. L.; Shaginian, R. M.; Deng, W.; Kendall, D. M.; Taskinen, M. R.; Smith, U.; et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: A randomized, controlled trial. Diabetes Care 2009, 32, 762-768. [PubMed]
57. Ding, X.; Saxena, N. K.; Lin, S.; Gupta, N. A.; Anania, F. A. Exendin-4, a glucagon-like protein-1 (glp-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006, 43, 173-181. [CrossRef] [PubMed]
58. Ali, E. S.; Hua, J.; Wilson, C. H.; Tallis, G. A.; Zhou, F. H.; Rychkov, G. Y.; Barritt, G. J. The glucagon-like peptide-1 analogue exendin-4 reverses impaired intracellular ca(2+) signalling in steatotic hepatocytes. Biochim. Biophys. Acta 2016, 1863, 2135-2146. [PubMed]
59. Salvo, F.; Moore, N.; Arnaud, M.; Robinson, P.; Raschi, E.; De Ponti, F.; Begaud, B.; Pariente, A. Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: Systematic review and meta-analysis. BMJ (Clin. Res. Ed.) 2016, 353, i2231. [CrossRef] [PubMed]
60. Herman, G. A.; Bergman, A.; Liu, F.; Stevens, C.; Wang, A. Q.; Zeng, W.; Chen, L.; Snyder, K.; Hilliard, D.; Tanen, M.; et al. Pharmacokinetics and pharmacodynamic effects of the oral dpp-4 inhibitor sitagliptin in middle-aged obese subjects. J. Clin. Pharmacol. 2006, 46, 876-886. [CrossRef] [PubMed]
61. Alsaad, A. A.; Dhannoon, S. M.; Pantin, S. A.; Porter, I. E. Rare allergic reaction of the kidney: Sitagliptin-induced acute tubulointerstitial nephritis. BMJ Case Rep. 2016, 2016, bcr2016216297. [CrossRef] [PubMed]
62. McMurray, J. J.; Krum, H.; Abraham, W. T.; Dickstein, K.; Kober, L. V.; Desai, A. S.; Solomon, S. D.; Greenlaw, N.; Ali, M. A.; Chiang, Y.; et al. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. N. Engl. J. Med. 2016, 374, 1521-1532. [CrossRef] [PubMed]
63. Cohen, E. P.; Fish, B. L.; Moulder, J. E. Clinically relevant doses of enalapril mitigate multiple organ radiation injury. Radiat. Res. 2016, 185, 313-318. [PubMed]
64. Wang, W.; McKinnie, S. M.; Farhan, M.; Paul, M.; McDonald, T.; McLean, B.; Llorens-Cortes, C.; Hazra, S.; Murray, A. G.; Vederas, J. C.; et al. Angiotensin-converting enzyme 2 metabolizes and partially inactivates pyr-apelin-13 and apelin-17: Physiological effects in the cardiovascular system. Hypertension 2016, 68, 365-377. [CrossRef] [PubMed]
65. Strauss, M. H.; Hall, A. S. Angiotensin receptor blockers may increase risk of myocardial infarction: Unraveling the arb-mi paradox. Circulation 2006, 114, 838-854. [CrossRef] [PubMed]
66. Levy, B. I. How to explain the differences between renin angiotensin system modulators. Am. J. Hypertens. 2005, 18, 134s-141s. [CrossRef] [PubMed]
67. Reudelhuber, T. L. The continuing saga of the at2 receptor: A case of the good, the bad, and the innocuous. Hypertension 2005, 46, 1261-1262. [CrossRef] [PubMed]
68. Chopra, A. 11c-Labeled Telmisartan, an Angiotensin II Type 1 Receptor Antagonist. InMolecular Imaging and Contrast Agent Database (Micad); National Center for Biotechnology Information (US): Bethesda, MD, USA, 2004.
69. Prasa, D.; Hoffmann-Walbeck, P.; Barth, S.; Stedtler, U.; Ceschi, A.; Farber, E.; Genser, D.; Seidel, C.; Deters, M. Angiotensin ii antagonists-An assessment of their acute toxicity. Clin. Toxicol. (Phila) 2013, 51, 429-434. [CrossRef] [PubMed]
70. Delaney, J. A.; Opatrny, L.; Brophy, J. M.; Suissa, S. Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. Can. Med. Assoc. J. 2007, 177, 347-351. [CrossRef] [PubMed]
71. Fiorucci, S.; Santucci, L.; Wallace, J. L.; Sardina, M.; Romano, M.; del Soldato, P.; Morelli, A. Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and no-releasing aspirin in the human gastric mucosa. Proc. Natl. Acad. Sci. USA 2003, 100, 10937-10941. [CrossRef] [PubMed]
72. Maessen-Visch, M. B.; de Roos, K. P. Dutch venous ulcer guideline update. Phlebology 2014, 29, 153-156. [CrossRef] [PubMed]
73. Romano, M.; Cianci, E.; Simiele, F.; Recchiuti, A. Lipoxins and aspirin-triggered lipoxins in resolution of inflammation. Eur. J. Pharmacol. 2015, 760, 49-63. [CrossRef] [PubMed]
74. Serhan, C. N.; Chiang, N. Resolution phase lipid mediators of inflammation: Agonists of resolution. Curr. Opin. Pharmacol. 2013, 13, 632-640. [CrossRef] [PubMed]
75. McCrindle, B. W.; Ose, L.; Marais, A. D. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: A multicenter, randomized, placebo-controlled trial. J. Pediatr. 2003, 143, 74-80. [CrossRef]
76. Nissen, S. E.; Nicholls, S. J.; Sipahi, I.; Libby, P.; Raichlen, J. S.; Ballantyne, C. M.; Davignon, J.; Erbel, R.; Fruchart, J. C.; Tardif, J. C.; et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The asteroid trial. JAMA 2006, 295, 1556-1565. [CrossRef] [PubMed]
77. Sever, P. S.; Dahlof, B.; Poulter, N. R.; Wedel, H.; Beevers, G.; Caulfield, M.; Collins, R.; Kjeldsen, S. E.; Kristinsson, A.; McInnes, G. T.; et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the anglo-scandinavian cardiac outcomes trial-lipid lowering arm (ascot-lla): A multicentre randomised controlled trial. Drugs 2004, 64 (Suppl. 2), 43-60.
78. Colhoun, H. M.; Betteridge, D. J.; Durrington, P. N.; Hitman, G. A.; Neil, H. A.; Livingstone, S. J.; Thomason, M. J.; Mackness, M. I.; Charlton-Menys, V.; Fuller, J. H. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (cards): Multicentre randomised placebo-controlled trial. Lancet (Lond. Engl.) 2004, 364, 685-696. [CrossRef]
79. Kostapanos, M. S.; Liamis, G. L.; Milionis, H. J.; Elisaf, M. S. Do statins beneficially or adversely affect glucose homeostasis? Curr. Vasc. Pharmacol. 2010, 8, 612-631. [CrossRef] [PubMed]
80. Ghirlanda, G.; Oradei, A.; Manto, A.; Lippa, S.; Uccioli, L.; Caputo, S.; Greco, A. V.; Littarru, G. P. Evidence of plasma coq10-lowering effect by hmg-coa reductase inhibitors: A double-blind, placebo-controlled study. J. Clin. Pharmacol. 1993, 33, 226-229. [CrossRef] [PubMed]
81. Gehlbach, P.; Li, T.;Hatef, E. Statins for age-relatedmacular degeneration. CochraneDatabase Syst. Rev. 2016, Cd006927.
82. Guymer, R. H.; Baird, P. N.; Varsamidis, M.; Busija, L.; Dimitrov, P. N.; Aung, K. Z.; Makeyeva, G. A.; Richardson, A. J.; Lim, L.; Robman, L. D. Proof of concept, randomized, placebo-controlled study of the effect of simvastatin on the course of age-related macular degeneration. PLoS ONE 2013, 8, e83759. [CrossRef] [PubMed]
83. Link, E.; Parish, S.; Armitage, J.; Bowman, L.; Heath, S.; Matsuda, F.; Gut, I.; Lathrop, M.; Collins, R. Slco1b1 variants and statin-induced myopathy-A genomewide study. N. Engl. J. Med. 2008, 359, 789-799. [PubMed]
84. Ramsey, L. B.; Johnson, S. G.; Caudle, K. E.; Haidar, C. E.; Voora, D.; Wilke, R. A.; Maxwell, W. D.; McLeod, H. L.; Krauss, R. M.; Roden, D. M.; et al. The clinical pharmacogenetics implementation consortium guideline for slco1b1 and simvastatin-induced myopathy: 2014 update. Clin. Pharmacol. Ther. 2014, 96, 423-428. [CrossRef] [PubMed]
85. Jones, P. H.; Davidson, M. H.; Stein, E. A.; Bays, H. E.; McKenney, J. M.; Miller, E.; Cain, V. A.; Blasetto, J. W. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (stellar trial). Am. J. Cardiol. 2003, 92, 152-160. [CrossRef]
86. McTaggart, F.; Jones, P. Effects of statins on high-density lipoproteins: A potential contribution to cardiovascular benefit. Cardiovasc. Drugs Ther. 2008, 22, 321-338. [CrossRef] [PubMed]
87. Greig, S. L.; Deeks, E. D. Alirocumab: A review in hypercholesterolemia. Am. J. Cardiovasc. Drugs 2016, 16, 141-152. [CrossRef] [PubMed]
88. Cannon, C. P.; Blazing, M. A.; Giugliano, R. P.; McCagg, A.; White, J. A.; Theroux, P.; Darius, H.; Lewis, B. S.; Ophuis, T. O.; Jukema, J. W.; et al. Ezetimibe added to statin therapy after acute coronary syndromes. N. Engl. J. Med. 2015, 372, 2387-2397. [CrossRef] [PubMed]
89. Teramoto, T.; Sasaki, J.; Ishibashi, S.; Birou, S.; Daida, H.; Dohi, S.; Egusa, G.; Hiro, T.; Hirobe, K.; Iida, M.; et al. Diabetes mellitus. Executive summary of the japan atherosclerosis society (jas) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in japan-2012 version. J. Atheroscler. Thromb. 2014, 21, 93-98. [CrossRef] [PubMed]
90. Chanson, N.; Bossi, P.; Schneider, L.; Bourry, E.; Izzedine, H. Rhabdomyolysis after ezetimibe/simvastatin therapy in an hiv-infected patient. NDT Plus 2008, 1, 157-161. [CrossRef] [PubMed]
91. Merten, D. F.; Grossman, H. Intestinal obstruction associated with cholestyramine therapy. AJR Am. J. Roentgenol. 1980, 134, 827-828. [CrossRef] [PubMed]
92. Jacobson, T. A.; Armani, A.; McKenney, J. M.; Guyton, J. R. Safety considerations with gastrointestinally active lipid-lowering drugs. Am. J. Cardiol. 2007, 99, 47c-55c. [CrossRef] [PubMed]
93. Handelsman, Y. Role of bile acid sequestrants in the treatment of type 2 diabetes. Diabetes Care 2011, 34 (Suppl. 2), S244-S250. [CrossRef] [PubMed]
94. Beigel, F.; Teich, N.; Howaldt, S.; Lammert, F.; Maul, J.; Breiteneicher, S.; Rust, C.; Goke, B.; Brand, S.; Ochsenkuhn, T. Colesevelam for the treatment of bile acid malabsorption-associated diarrhea in patients with crohn's disease: A randomized, double-blind, placebo-controlled study. J. Crohns Colitis 2014, 8, 1471-1479. [CrossRef] [PubMed]
95. Fonseca, V. A.; Rosenstock, J.;Wang, A. C.; Truitt, K. E.; Jones, M. R. Colesevelam hcl improves glycemic control and reduces ldl cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 2008, 31, 1479-1484. [CrossRef] [PubMed]
96. Rodney, G.; Uhlendorf, P.; Maxwell, R. E. The hypolipidaemic effect of gemfibrozil (ci-719) in laboratory animals. Proc. R. Soc. Med. 1976, 69 (Suppl. 2), 6-10.
97. Fitzgerald, J. E.; Sanyer, J. L.; Schardein, J. L.; Lake, R. S.; McGuire, E. J.; de la Iglesia, F. A. Carcinogen bioassay and mutagenicity studies with the hypolipidemic agent gemfibrozil. J. Natl. Cancer Inst. 1981, 67, 1105-1116. [PubMed]
98. Yang, L. P.; Keating, G. M. Fenofibric acid: In combination therapy in the treatment of mixed dyslipidemia. Am. J. Cardiovasc. Drugs 2009, 9, 401-409. [CrossRef] [PubMed]
99. Wong, T. Y.; Simo, R.; Mitchell, P. Fenofibrate-A potential systemic treatment for diabetic retinopathy? Am. J. Ophthalmol. 2012, 154, 6-12. [CrossRef] [PubMed]
100. Keene, D.; Price, C.; Shun-Shin, M. J.; Francis, D. P. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and cetp inhibitors: Meta-analysis of randomised controlled trials including 117, 411 patients. BMJ (Clin. Res. Ed.) 2014, 349, g4379. [CrossRef] [PubMed]
101. Garg, A.; Sharma, A.; Krishnamoorthy, P.; Garg, J.; Virmani, D.; Sharma, T.; Stefanini, G.; Kostis, J. B.; Mukherjee, D.; Sikorskaya, E. Role of niacin in current clinical practice: A systematic review. Am. J. Med. 2017, 130, 173-187. [CrossRef] [PubMed]
102. Katzmarzyk, P. T.; Leon, A. S.; Wilmore, J. H.; Skinner, J. S.; Rao, D. C.; Rankinen, T.; Bouchard, C. Targeting the metabolic syndrome with exercise: Evidence from the heritage family study. Med. Sci. Sports Exerc. 2003, 35, 1703-1709. [CrossRef] [PubMed]
103. Feldeisen, S. E.; Tucker, K. L. Nutritional strategies in the prevention and treatment of metabolic syndrome. Appl. Physiol. Nutr. Metab. 2007, 32, 46-60. [CrossRef] [PubMed]
104. Lakka, T. A.; Laaksonen, D. E. Physical activity in prevention and treatment of the metabolic syndrome. Appl. Physiol. Nutr. Metab. 2007, 32, 76-88. [CrossRef] [PubMed]
105. Allison, D. B.; Gadde, K. M.; Garvey, W. T.; Peterson, C. A.; Schwiers, M. L.; Najarian, T.; Tam, P. Y.; Troupin, B.; Day, W. W. Controlled-release phentermine/topiramate in severely obese adults: A randomized controlled trial (equip). Obesity 2012, 20, 330-342. [CrossRef] [PubMed]
106. Smith, S. M.;Meyer, M.; Trinkley, K. E. Phentermine/topiramate for the treatment of obesity. Ann. Pharmacother. 2013, 47, 340-349. [CrossRef] [PubMed]
107. Khera, R.; Murad, M. H.; Chandar, A. K.; Dulai, P. S.;Wang, Z.; Prokop, L. J.; Loomba, R.; Camilleri, M.; Singh, S. Association of pharmacological treatments for obesity with weight loss and adverse events: A systematic review and meta-analysis. JAMA 2016, 315, 2424-2434. [CrossRef] [PubMed]
108. James, W. P. T.; Caterson, I. D.; Coutinho, W.; Finer, N.; Van Gaal, L. F.; Maggioni, A. P.; Torp-Pedersen, C.; Sharma, A. M.; Shepherd, G. M.; Rode, R. A.; et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N. Engl. J. Med. 2010, 363, 905-917. [CrossRef] [PubMed]
109. Berstein, L. M. Metformin in obesity, cancer and aging: Addressing controversies. Aging (Albany N. Y.) 2012, 4, 320-329. [CrossRef] [PubMed]
110. Round, J. L.; Mazmanian, S. K. The gut microbiome shapes intestinal immune responses during health and disease. Nat. Rev. Immunol. 2009, 9, 313. [CrossRef] [PubMed]
111. Su, C.; Lei, L.; Duan, Y.; Zhang, K.-Q.; Yang, J. Culture-independent methods for studying environmental microorganisms: Methods, application, and perspective. Appl. Microbiol. Biotechnol. 2012, 93, 993-1003. [CrossRef] [PubMed]
112. Palmer, C.; Bik, E. M.; DiGiulio, D. B.; Relman, D. A.; Brown, P. O. Development of the human infant intestinal microbiota. PLoS Biol. 2007, 5, e177. [CrossRef] [PubMed]
113. Koenig, J. E.; Spor, A.; Scalfone, N.; Fricker, A. D.; Stombaugh, J.; Knight, R.; Angenent, L. T.; Ley, R. E. Succession of microbial consortia in the developing infant gut microbiome. Proc. Natl. Acad. Sci. USA 2011, 108, 4578-4585. [CrossRef] [PubMed]
114. Faith, J. J.; Guruge, J. L.; Charbonneau, M.; Subramanian, S.; Seedorf, H.; Goodman, A. L.; Clemente, J. C.; Knight, R.; Heath, A. C.; Leibel, R. L. The long-term stability of the human gut microbiota. Science 2013, 341, 1237439. [CrossRef] [PubMed]
115. Consortium, H. M. P. Structure, function and diversity of the healthy human microbiome. Nature 2012, 486, 207-214.
116. DeGruttola, A. K.; Low, D.; Mizoguchi, A.; Mizoguchi, E. Current understanding of dysbiosis in disease in human and animal models. Inflamm. Bowel. Dis. 2016, 22, 1137. [CrossRef] [PubMed]
117. Bergman, E. Energy contributions of volatile fatty acids from the gastrointestinal tract in various species. Physiol. Rev. 1990, 70, 567-590. [PubMed]
118. Flint, H. J.; Scott, K. P.; Duncan, S. H.; Louis, P.; Forano, E. Microbial degradation of complex carbohydrates in the gut. Gut Microbes 2012, 3, 289-306. [CrossRef] [PubMed]
119. Wostmann, B. S.; Larkin, C.; Moriarty, A.; Bruckner-Kardoss, E. Dietary intake, energy metabolism, and excretory losses of adult male germfree wistar rats. Lab. Anim. Sci. 1983, 33, 46-50. [PubMed]
120. Ley, R. E.; Bäckhed, F.; Turnbaugh, P.; Lozupone, C. A.; Knight, R. D.; Gordon, J. I. Obesity alters gut microbial ecology. Proc. Natl. Acad. Sci. USA 2005, 102, 11070-11075. [CrossRef] [PubMed]
121. Ley, R. E.; Turnbaugh, P. J.; Klein, S.; Gordon, J. I. Microbial ecology: Human gut microbes associated with obesity. Nature 2006, 444, 1022-1023. [CrossRef] [PubMed]
122. Turnbaugh, P. J.; Ley, R. E.; Mahowald, M. A.; Magrini, V.; Mardis, E. R.; Gordon, J. I. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006, 444, 1027-1131. [CrossRef] [PubMed]
123. Duncan, S. H.; Hold, G. L.; Barcenilla, A.; Stewart, C. S.; Flint, H. J. Roseburia intestinalis sp. Nov., a novel saccharolytic, butyrate-producing bacterium from human faeces. Int. J. Syst. Evol. Microbiol. 2002, 52, 1615-1620. [PubMed]
124. Drissi, F.; Merhej, V.; Angelakis, E.; El Kaoutari, A.; Carriere, F.; Henrissat, B.; Raoult, D. Comparative genomics analysis of lactobacillus species associated with weight gain or weight protection. Nutr. Diabetes 2014, 4, e109. [CrossRef] [PubMed]
125. Turnbaugh, P. J.; Hamady, M.; Yatsunenko, T.; Cantarel, B. L.; Duncan, A.; Ley, R. E.; Sogin, M. L.; Jones, W. J.; Roe, B. A.; Affourtit, J. P. A core gut microbiome in obese and lean twins. Nature 2009, 457, 480. [CrossRef] [PubMed]
126. Bäckhed, F.; Ding, H.;Wang, T.; Hooper, L. V.; Koh, G. Y.; Nagy, A.; Semenkovich, C. F.; Gordon, J. I. The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl. Acad. Sci. USA 2004, 101, 15718-15723. [CrossRef] [PubMed]
127. Bäckhed, F.; Manchester, J. K.; Semenkovich, C. F.; Gordon, J. I. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc. Natl. Acad. Sci. USA 2007, 104, 979-984. [CrossRef] [PubMed]
128. Greiner, T.; Bäckhed, F. Effects of the gut microbiota on obesity and glucose homeostasis. Trends Endocrinol. Metab. 2011, 22, 117-123. [CrossRef] [PubMed]
129. den Besten, G.; Lange, K.; Havinga, R.; van Dijk, T. H.; Gerding, A.; van Eunen, K.; Müller, M.; Groen, A. K.; Hooiveld, G. J.; Bakker, B. M. Gut-derived short-chain fatty acids are vividly assimilated into host carbohydrates and lipids. Am. J. Physiol. Gastrointest. Liver Physiol. 2013, 305, G900-G910. [CrossRef] [PubMed]
130. Singh, V.; Chassaing, B.; Zhang, L.; San Yeoh, B.; Xiao, X.; Kumar, M.; Baker, M. T.; Cai, J.; Walker, R.; Borkowski, K. Microbiota-dependent hepatic lipogenesis mediated by stearoyl coa desaturase 1 (scd1) promotes metabolic syndrome in tlr5-deficient mice. Cell Metab. 2015, 22, 983-996. [CrossRef] [PubMed]
131. Velagapudi, V. R.; Hezaveh, R.; Reigstad, C. S.; Gopalacharyulu, P.; Yetukuri, L.; Islam, S.; Felin, J.; Perkins, R.; Borén, J.; Oreši?c, M. The gut microbiota modulates host energy and lipid metabolism in mice. J. Lipid. Res. 2010, 51, 1101-1112. [CrossRef] [PubMed]
132. Fu, J.; Bonder, M. J.; Cenit, M. C.; Tigchelaar, E.; Maatman, A.; Dekens, J. A.; Brandsma, E.; Marczynska, J.; Imhann, F.;Weersma, R. K. The gut microbiome contributes to a substantial proportion of the variation in blood lipids. Circ. Res. 2015, 117, 817-824. [CrossRef] [PubMed]
133. Tang, W. W.; Hazen, S. L. The contributory role of gut microbiota in cardiovascular disease. J. Clin. Investig. 2014, 124, 4204-4211. [CrossRef] [PubMed]
134. Wang, Z.; Klipfell, E.; Bennett, B. J.; Koeth, R.; Levison, B. S.; DuGar, B.; Feldstein, A. E.; Britt, E. B.; Fu, X.; Chung, Y.-M. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011, 472, 57-63. [CrossRef] [PubMed]
135. Blandino, G.; Inturri, R.; Lazzara, F.; Di Rosa, M.; Malaguarnera, L. Impact of gut microbiota on diabetes mellitus. Diabetes Metab. 2016, 42, 303-315. [CrossRef] [PubMed]
136. Festi, D.; Schiumerini, R.; Eusebi, L. H.; Marasco, G.; Taddia, M.; Colecchia, A. Gut microbiota and metabolic syndrome. World J. Gastroenterol. 2014, 20, 16079-16094. [CrossRef] [PubMed]
137. Knip, M.; Siljander, H. The role of the intestinal microbiota in type 1 diabetes mellitus. Nat. Rev. Endocrinol. 2016, 12, 154-167. [CrossRef] [PubMed]
138. Atkinson, M. A.; Eisenbarth, G. S. Type 1 diabetes: New perspectives on disease pathogenesis and treatment. Lancet 2001, 358, 221-229. [CrossRef]
139. Qin, J.; Li, Y.; Cai, Z.; Li, S.; Zhu, J.; Zhang, F.; Liang, S.; Zhang, W.; Guan, Y.; Shen, D. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012, 490, 55-60. [CrossRef] [PubMed]
140. Karlsson, F. H.; Tremaroli, V.; Nookaew, I.; Bergström, G.; Behre, C. J.; Fagerberg, B.; Nielsen, J.; Bäckhed, F. Gut metagenome in european women with normal, impaired and diabetic glucose control. Nature 2013, 498, 99-103. [CrossRef] [PubMed]
141. Cani, P. D.; Osto, M.; Geurts, L.; Everard, A. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes 2012, 3, 279-288. [CrossRef] [PubMed]
142. Zhang, Y.; Zhang, H. Microbiota associated with type 2 diabetes and its related complications. Food Sci. Hum. Wellness 2013, 2, 167-172. [CrossRef]
143. Delzenne, N. M.; Cani, P. D. Gut microbiota and the pathogenesis of insulin resistance. Curr. Diabetes Rep. 2011, 11, 154-159. [CrossRef] [PubMed]
144. Pendyala, S.; Walker, J. M.; Holt, P. R. A high-fat diet is associated with endotoxemia that originates from the gut. Gastroenterology 2012, 142, 1100-1101. [CrossRef] [PubMed]
145. Cani, P. D.; Amar, J.; Iglesias, M. A.; Poggi, M.; Knauf, C.; Bastelica, D.; Neyrinck, A. M.; Fava, F.; Tuohy, K. M.; Chabo, C. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007, 56, 1761-1772. [CrossRef] [PubMed]
146. Cani, P. D.; Bibiloni, R.; Knauf, C.; Waget, A.; Neyrinck, A. M.; Delzenne, N. M.; Burcelin, R. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008, 57, 1470-1481. [CrossRef] [PubMed]
147. Yang, T.; Santisteban, M. M.; Rodriguez, V.; Li, E.; Ahmari, N.; Carvajal, J. M.; Zadeh, M.; Gong, M.; Qi, Y.; Zubcevic, J. Gut dysbiosis is linked to hypertensionnovelty and significance. Hypertension 2015, 65, 1331-1340. [CrossRef] [PubMed]
148. Li, J.; Zhao, F.; Wang, Y.; Chen, J.; Tao, J.; Tian, G.; Wu, S.; Liu, W.; Cui, Q.; Geng, B. Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome 2017, 5, 14. [CrossRef] [PubMed]
149. Conlon, M. A.; Bird, A. R. The impact of diet and lifestyle on gut microbiota and human health. Nutrients 2014, 7, 17-44. [CrossRef] [PubMed]
150. Sonnenburg, J. L.; Bäckhed, F. Diet-microbiota interactions as moderators of human metabolism. Nature 2016, 535, 56-64. [CrossRef] [PubMed]
151. Fetissov, S. O. Role of the gut microbiota in host appetite control: Bacterial growth to animal feeding behaviour. Nat. Rev. Endocrinol. 2017, 13, 11-25. [CrossRef] [PubMed]
152. Chen, X.; D'Souza, R.; Hong, S.-T. The role of gut microbiota in the gut-brain axis: Current challenges and perspectives. Protein Cell 2013, 4, 403-414. [CrossRef] [PubMed]
153. Vancampfort, D.; Correll, C. U.; Wampers, M.; Sienaert, P.; Mitchell, A.; De Herdt, A.; Probst, M.; Scheewe, T. W.; De Hert, M. Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: A meta-analysis of prevalences and moderating variables. Psychol. Med. 2014, 44, 2017-2028. [CrossRef] [PubMed]
154. Lieberman, J. A., III. Metabolic changes associatedwith antipsychotic use. Prim. Care Companion J. Clin. Psychiatry 2004, 6, 8. [PubMed]
155. Desbonnet, L.; Garrett, L.; Clarke, G.; Kiely, B.; Cryan, J.; Dinan, T. Effects of the probiotic bifidobacterium infantis in the maternal separation model of depression. Neuroscience 2010, 170, 1179-1188. [CrossRef] [PubMed]
156. Bravo, J. A.; Forsythe, P.; Chew, M. V.; Escaravage, E.; Savignac, H. M.; Dinan, T. G.; Bienenstock, J.; Cryan, J. F. Ingestion of lactobacillus strain regulates emotional behavior and central gaba receptor expression in a mouse via the vagus nerve. Proc. Natl. Acad. Sci. USA 2011, 108, 16050-16055. [CrossRef] [PubMed]